Over the weekend Sinovac Biotech ’s semi-annual report hit the screens. It’s truly terrifying to have made a net profit of more than 50 billion in half a year! It’s so profitable! The profitability of the medical industry is so powerful that it amazes everyone!
Let’s look at Jiu’an Medical . The company stated in an institutional survey on December 29 that as of December 27, U.S. time, it had received Massachusetts and other government orders for a total of 47.43 million units, and has shipped 8.82 million units so far. 62.55 million U.S. dollars (including advance payment) have been received, and the uncollected order amount is 174.6 million U.S. dollars. The sales amount of commercial customers was US$36.19 million, and the sales amount of the company's website and Amazon in the United States was US$68.35 million. Taken together, the orders on hand that have been sold so far have reached 341 million US dollars, which is equivalent to revenue of 2.171 billion yuan. According to the guaranteed minimum gross profit rate of 50%, it has contributed at least 1.08 billion in net profit, and the corresponding price-earnings ratio is less than 20 times!
key This may be just the beginning, this is just the order situation that has been announced. So is there any room for addition or imagination?
Looking at the new crown epidemic situation in the United States over the weekend, it has been running at a high level for several days in a row. Yesterday, there were 254,000, which was the lowest number in recent days. The highest number in recent days was more than 600,000 infections in one day.
Omicron is currently very transmissible, but the severity and fatality rates have declined. The ICU bed utilization rate in the United States has reached more than 70%. At present, the United States has urgently approved Pfizer 's oral COVID-19 drug. The purpose is to rely on drugs to prevent and control the disease as much as possible, while hospitals focus on treating severe cases. It is absolutely impossible to imitate China and clear the country. Maybe we in China will eventually have to imitate the United States when conditions are ripe.
So, what conditions would be required if people in the United States were allowed to take their own medicine to treat the new coronavirus?
First, there must be enough effective drugs.
The second is to be able to diagnose and confirm the new crown in a timely manner. That is, you must first know what disease you have before you can choose the corresponding medicine. For the common cold , use cold medicine, and for the new coronavirus, use COVID-19 medicine. At this time, the importance, convenience and low cost of home testing reagents are reflected.
If we have clarified this procedure and principle, we will know that home-use COVID-19 testing reagents are a necessary condition for large-scale self-service treatment by the public. In this way, Jiu'an Medical's testing reagents will play a big role.
So, does the current share price of Jiu'an Medical reflect the market's expectations?
looks from the disk. The main funds continued to flee, with 1.3 billion escaping on Friday, which can be said to be unprecedented in recent times, with a turnover of 6.1 billion. The after-hours list showed that hot money collectively fled, and retail investors fully took over. It's over, this is the rhythm of falling to the limit of . The retail investors inside are trembling, and it is a foregone conclusion that it will open lower on Tuesday.
If the market fluctuates sideways for a few days, what happens after the chips change hands? If there is news about new orders at this time, this possibility is entirely possible, and then the third wave of daily limit increases will come.
If there is no third wave, what is the biggest risk? Unless a large-scale similar product appears in the market, just like the original masks, with the intervention of large-scale enterprises, the production and manufacturing threshold is low, and it will soon become a cabbage price. The price of Dawn Share will naturally plummet and continue to fall. Got it! However, test kits are not masks and cannot be made by a clothing factory or BYD by modifying a production line. In the short term, supply will exceed demand, and there won't be that many competitors.
US FDA has been obtained. Has the company applied for EU EDA? Will the EU market be opened in the future? There is room for imagination. Overall,
is an industry leader and a high-profit enterprise with huge demand. The valuation of 23 billion is not high, and it should still be popular in the spotlight! After adjusting
, I will check the disk later to verify my opinion.
The above is my personal opinion! This is not a call for everyone to take over, but a discussion of possible future trends and logic! For your communication and reference only!
